A ONCE-DAILY ORAL JAK inhibitor indicated for the treatment of adults and pediatric patients 12+ years of age with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.1
SKIN CLEARANCE AND ITCH REDUCTION TO
DISRUPT
THE ITCH AND RASH OF ATOPIC DERMATITIS
SKIN CLEARANCE DATA
Proportion of patients achieving EASI 75 skin clearance
Rapid, controlled skin clearance at Week 161,2*


RINVOQ 15 mg (n=281)
RINVOQ 30 mg (n=285)
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
RINVOQ 15 mg (n=276)
RINVOQ 30 mg (n=282)
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
RECOMMENDED DOSAGE IN AD1:
- 30 mg is not an approved starting dose
- For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
- For 65+ years: Recommended dosage is 15 mg once daily
The co-primary endpoints1
were the percentage of patients achieving EASI 75 and a vIGA score of 0/1 at Week 16
vIGA 0/1 at Week 161,2:
8%Placebo
48%†RINVOQ 15 mg
62%†RINVOQ 30 mg
RECOMMENDED DOSAGE IN AD1:
- 30 mg is not an approved starting dose
- For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
- For 65+ years: Recommended dosage is 15 mg once daily
THE CO-PRIMARY ENDPOINTS1
were the percentage of patients achieving EASI 75 and a vIGA score of 0/1 at Week 16
vIGA 0/1 at Week 161,2:
5%Placebo
39%†RINVOQ 15 mg
52%†RINVOQ 30 mg
Durable skin clearance rates at Week 52 in a blinded extension study5,6*
INTEGRATED RESULTS FROM MEASURE UP 1 AND 2;
ALL DATA ARE OBSERVED CASES

RINVOQ 15 mg
RINVOQ 30 mg
*Monotherapy results. OC; ITT. Data are a sub-analysis of the MEASURE UP blinded extension data including only patients who were originally randomized to RINVOQ, completed the RCT, and enrolled in the blinded extension.
RECOMMENDED DOSAGE IN AD1:
- 30 mg is not an approved starting dose
- For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
- For 65+ years: Recommended dosage is 15 mg once daily
DATA LIMITATIONS: Data through Week 52 were prespecified, non-ranked endpoints, not controlled for multiplicity; results cannot be considered statistically significant.
OLE LIMITATIONS: There is potential for enrichment of OLE data, as those who remain in the study are aware of their treatment and generally fare better than those who discontinue. Patients may have used topical medications.
Proportion of patients achieving EASI 90 skin clearance
Robust EASI 90 skin clearance measured at Week 161,2*


RINVOQ 15 mg (n=281)
RINVOQ 30 mg (n=285)
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
RINVOQ 15 mg (n=276)
RINVOQ 30 mg (n=282)
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
RECOMMENDED DOSAGE IN AD1:
- 30 mg is not an approved starting dose
- For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
- For 65+ years: Recommended dosage is 15 mg once daily
THE CO-PRIMARY ENDPOINTS1
were the percentage of patients achieving EASI 75 and a vIGA score of 0/1 at Week 16
RANKED SECONDARY ENDPOINT1
included percentage of patients achieving EASI 90 at Week 16
vIGA 0/1 AT WEEK 161,2:
8%Placebo
48%†RINVOQ 15 mg
62%†RINVOQ 30 mg
RECOMMENDED DOSAGE IN AD1:
- 30 mg is not an approved starting dose
- For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
- For 65+ years: Recommended dosage is 15 mg once daily
THE CO-PRIMARY ENDPOINTS1
were the percentage of patients achieving EASI 75 and a vIGA score of 0/1 at Week 16
RANKED SECONDARY ENDPOINT1
included percentage of patients achieving EASI 90 at Week 16
vIGA 0/1 AT WEEK 161,2:
5%Placebo
39%†RINVOQ 15 mg
52%†RINVOQ 30 mg
Durable skin clearance rates at Week 52 in a blinded extension study5,6*
INTEGRATED RESULTS FROM MEASURE UP 1 AND 2;
ALL DATA ARE OBSERVED CASES

RINVOQ 15 mg
RINVOQ 30 mg
*Monotherapy results. OC; ITT. Data are a sub-analysis of the MEASURE UP blinded extension data including only patients who were originally randomized to RINVOQ, completed the RCT, and enrolled in the blinded extension.
RECOMMENDED DOSAGE IN AD1:
- 30 mg is not an approved starting dose
- For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
- For 65+ years: Recommended dosage is 15 mg once daily
DATA LIMITATIONS: Data through Week 52 were prespecified, non-ranked endpoints, not controlled for multiplicity; thus, results cannot be considered statistically significant.
OLE LIMITATIONS: There is potential for enrichment of OLE data, as those who remain in the study are aware of their treatment and generally fare better than those who discontinue. Patients may have used topical medications.
Visible results at Week 16 with RINVOQ3
EASI 75
(Co-primary endpoint)1
Actual MEASURE UP patients treated with RINVOQ (15 mg) in a clinical trial. Individual results may vary.
EASI 90
(Ranked secondary endpoint)2
ITCH RELIEF DATA
Proportion of patients with improvement in worst pruritus NRS ≥4
Rapid, controlled itch relief at
Week 161,2*






RINVOQ 15 mg (n=274)
RINVOQ 30 mg (n=280)
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
RINVOQ 15 mg (n=270)
RINVOQ 30 mg (n=280)
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
RECOMMENDED DOSAGE IN AD1:
- 30 mg is not an approved starting dose
- For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
- For 65+ years: Recommended dosage is 15 mg once daily
THE CO-PRIMARY ENDPOINTS1
were the percentage of patients achieving EASI 75 and a vIGA score of 0/1 at Week 16
RANKED SECONDARY ENDPOINT2
RESPONSES OBSERVED AS EARLY AS
2 DAYSafter 1st dose:
16%†RINVOQ 15 mg (n=275)
3%Placebo (n=270)
RECOMMENDED DOSAGE IN AD1:
- 30 mg is not an approved starting dose
- For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
- For 65+ years: Recommended dosage is 15 mg once daily
THE CO-PRIMARY ENDPOINTS1
were the percentage of patients achieving EASI 75 and a vIGA score of 0/1 at Week 16
RANKED SECONDARY ENDPOINT2
RESPONSES OBSERVED AS EARLY AS
2 DAYSafter 1st dose:
12%†RINVOQ 15 mg (n=269)
3%Placebo (n=267)
Durable rates of itch relief at Week 52 in a blinded extension study5,6*
INTEGRATED RESULTS FROM MEASURE UP 1 AND 2;
ALL DATA ARE OBSERVED CASES



RINVOQ 15 mg
RINVOQ 30 mg
*Monotherapy results. OC; ITT. Data are a sub-analysis of the MEASURE UP blinded extension data including only patients who were originally randomized to RINVOQ, completed the RCT, and enrolled in the blinded extension.
RECOMMENDED DOSAGE IN AD1:
- 30 mg is not an approved starting dose
- For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
- For 65+ years: Recommended dosage is 15 mg once daily
DATA LIMITATIONS: Data through Week 52 were prespecified, non-ranked endpoints, not controlled for multiplicity; thus, results cannot be considered statistically significant.
OLE LIMITATIONS: There is potential for enrichment of OLE data, as those who remain in the study are aware of their treatment and generally fare better than those who discontinue. Patients may have used topical medications.